Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 2/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 5/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | WNT3 | P56703 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3251568 | 0.87 | PARG (0.48) | PARGKDM4EMEN1POLBCYP2C9 | |
| SCHEMBL3255657 | 0.86 | PARG (0.38) | CCR8SFRP1BRD4PARGKDM4E | |
| SCHEMBL3255653 | 0.86 | PARG (0.38) | CCR8SFRP1BRD4PARGKDM4E | |
| SCHEMBL3243012 | 0.85 | PARG (0.56) | BRD4PARGKDM4EMEN1POLB | |
| SCHEMBL3242536 | 0.84 | TDP1 (0.53) | PARGKDM4EPOLBTDP1ALDH1A1 | |
| SCHEMBL3248538 | 0.83 | TDP1 (0.54) | PARGKDM4EMEN1POLBKMT2A | |
| SCHEMBL3249968 | 0.83 | TDP1 (0.54) | PARGKDM4EMEN1POLBKMT2A | |
| SCHEMBL3245470 | 0.82 | PARG (0.50) | CCR8SFRP1PARGKDM4EMEN1 | |
| SCHEMBL3242728 | 0.80 | KDM4E (0.45) | BRD4KDM4EMEN1POLBCYP2C9 | |
| SCHEMBL3242979 | 0.80 | KDM4E (0.45) | BRD4KDM4EMEN1POLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | CCR8 2915/4885SFRP1 3736/4885BRD4 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.